Suchergebnisse - "Zink, Angela"

PubPharm (10)

1

Sustainability of rituximab therapy in different treatment strategies : results of a 3-year followup of a German biologics register

enthalten in: Arthritis care & research | 2014

von Richter, A. | Strangfeld, A. | Herzer, P. | +4

2

Detection and evaluation of a drug safety signal concerning pancreatic cancer : lessons from a joint approach of three European biologics registers

enthalten in: Rheumatology (Oxford, England) | 2011

von Strangfeld, A. | Hyrich, K. | Askling, J. | +8

3

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany

enthalten in: PharmacoEconomics | 2005

von Schädlich, P. | Zeidler, H. | Zink, A. | +5

4

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany

enthalten in: PharmacoEconomics | 2005

von Schädlich, P. | Zeidler, H. | Zink, A. | +5

5

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany

enthalten in: PharmacoEconomics | 2005

von Schädlich, P. | Zeidler, H. | Zink, A. | +5

6

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany

enthalten in: PharmacoEconomics | 2005

von Schädlich, P. | Zeidler, H. | Zink, A. | +5

7

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany

enthalten in: PharmacoEconomics | 2005

von Schädlich, P. | Zeidler, H. | Zink, A. | +5

8

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany

enthalten in: PharmacoEconomics | 2005

von Schädlich, P. | Zeidler, H. | Zink, A. | +5

9

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany : I. Selected DMARDs and patient-related costs

enthalten in: PharmacoEconomics | 2005

von Schädlich, P. | Zeidler, H. | Zink, A. | +5

10

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany : II. The contribution of leflunomide to efficiency

enthalten in: PharmacoEconomics | 2005

von Schädlich, P. | Zeidler, H. | Zink, A. | +5

1
[1]